Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and remains one of the leading causes of cancer-related deaths worldwide. Despite advances in targeted therapies and immunotherapy, substantial molecular heterogeneity continues to limit accurate prognostic prediction and effective treatment selection. While metabolic reprogramming is increasingly recognized as a hallmark of HCC, the contribution of lipid droplet-associated genes (LDAGs) to tumor classification and disease progression has remained poorly defined.